Boehringer Ingelheim

February 9, 2018February 9, 2018

Yale Study Reveals the Role a Previously Overlooked Cell Type Plays in IPF Progression

A new study from Yale University has found that cells located along the walls of small blood vessels in the lung, called pericytes, promote the progression of idiopathic pulmonary fibrosis (IPF). The ... Read more

January 17, 2018January 17, 2018

Health Canada Issues Safety Warning on Pulmonary Fibrosis Therapy Ofev

Idiopathic Pulmonary Fibrosis, News

Reports of liver injuries stemming from the pulmonary fibrosis therapy Ofev (nintedanib), including a fatality, have prompted Health Canada to issue a safety warning about it to medical professionals. The regulatory agency said ... Read more

December 13, 2017December 13, 2017

ALCF, Boehringer Ingelheim Bring Gift of Volunteer Help to Lung Cancer Patients

Lung Cancer, News

The Bonnie J. Addario Lung Cancer Foundation (ALCF) and the employees at Boehringer Ingelheim Pharmaceuticals have joined forces to help brighten the holiday season for lung cancer patients through the “Bring Hope ... Read more

November 16, 2017November 16, 2017

Ofev Slows Scarring in Pulmonary Fibrosis Patients’ Lungs, Phase 3b Trial Shows

Idiopathic Pulmonary Fibrosis, News

Boehringer Ingelheim’s Ofev (nintedanib) slows scarring in idiopathic pulmonary fibrosis patients’ lungs, a Phase 3b trial indicates. The company used an imaging technique to check on Ofev’s anti-fibrotic properties. It was the ... Read more

November 14, 2017November 14, 2017

ATS Foundation, Boehringer Ingelheim Fund New Fellowship on IPF Research

Idiopathic Pulmonary Fibrosis, News

The American Thoracic Society (ATS) Foundation and Boehringer Ingelheim have jointly launched a new research fellowship in idiopathic pulmonary fibrosis (IPF), aiming to grant young investigators $100,000 over a two-year period from ... Read more

November 1, 2017November 1, 2017

Prometic’s Pulmonary Fibrosis Therapy PBI-4050 Earns FDA Fast Track Status

Idiopathic Pulmonary Fibrosis

The U.S. Food and Drug and Drug Administration has awarded Fast Track status to PBI-4050, Prometic Life Sciences‘ treatment for lung scarring in idiopathic pulmonary fibrosis. The Fast Track designation ... Read more

October 26, 2017October 26, 2017

Early Analysis of Ofev in INPULSIS-ON Trial Shows Long-Term Effectiveness in Treating IPF

News

The therapy Ofev (nintedanib) was shown to slow down the progression of idiopathic pulmonary fibrosis (IPF) through 96 weeks, regardless of a patient’s lung disease severity at the beginning of the study ... Read more

October 24, 2017October 24, 2017

Ofev Improves IPF Patients’ Lung Function Over the Long Term, Trial and Extension Show

Idiopathic Pulmonary Fibrosis, News

Long-term treatment with Boehringer Ingelheim‘s Ofev (nintedanib) improved the lung function and reduced the flare-ups of people with idiopathic pulmonary fibrosis, results of a Phase 2 clinical trial and its extension show. ... Read more

October 19, 2017October 19, 2017

FDA Giving Priority Review to Gilotriftm as Treatment for Rare Form of Lung Cancer

Lung Cancer, News

The U.S. Food and Drug Administration is giving priority review to Boehringer Ingelheim’s request that the agency consider approving Gilotriftm (afatinib) for an additional category of lung cancer patients. Gilotriftm is already approved ... Read more

October 2, 2017October 2, 2017

Prometic Gets FDA Approval to Start Phase 2/3 Trial of PBI-4050 in IPF Patients

Idiopathic Pulmonary Fibrosis, News

Prometic Life Sciences announced that PBI-4050, its investigational therapy for idiopathic pulmonary fibrosis (IPF), has been cleared by the U.S. Food and Drug Administration (FDA) to enter a Phase 2/3 combination-treatment trial in the ... Read more